Subscribe To
Biocryst reports third quarter 2023 financial results and provides business update
– Q3 2023 orladeyo net revenue of $85.7 million (+29.8 percent y-o-y) — – Company expects to achi...
November 2, 2023, 11:00 am
Biocryst pharmaceuticals rallies on quebec reimbursement for orladeyo angioedema treatment
BioCryst Pharmaceuticals (NASDAQ:BCRX) shares jumped in early Monday trading after it told investors that the Institut national d'excellence en santé...
September 18, 2023, 10:53 am
Biocryst selects er-kim pharmaceuticals as commercial partner for orladeyo® (berotralstat) in turkey
RESEARCH TRIANGLE PARK, N.C., July 19, 2023 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered...
July 19, 2023, 11:00 am
Biocryst to present new orladeyo® (berotralstat) data at 2023 european academy of allergy and clinical immunology congress
RESEARCH TRIANGLE PARK, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals Inc (Nasdaq: BCRX) today announced that the company will prese...
May 31, 2023, 7:02 am
Why biocryst pharmaceuticals stock is soaring today
BioCryst Pharmaceuticals reported first-quarter earnings Wednesday morning. The financial report painted an overall encouraging picture regarding its ...
May 3, 2023, 1:44 pm
Biocryst is not currently uncovering the full value of orladeyo
BioCryst's main value driver, ORLADEYO, is already profitable in its second year on the market and generated over $250 million in revenue in 2022.
February 22, 2023, 9:00 am
Pharmaceutical stock sinks on sales forecast
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) stock is sinking today, down 11.6% at $10.45 at last glance, after the company's sales forecast for its ski...
January 9, 2023, 3:10 pm
Biocryst pharmaceuticals: more aggressive growth for orladeyo
As a stellar drug for hereditary angioedema, BioCryst Pharmaceuticals' orladeyo is enjoying strong sale...
December 20, 2022, 4:47 pm
Is biocryst (bcrx) ready to breakout to new highs on recent catalysts?
By Ben Rabizadeh – Fundamentals well positioned with $1B peak sales forecast for orladeyo and $300M i...
February 9, 2022, 4:25 pm
Is biocryst (bcrx) ready to breakout to new highs on recent catalysts?
By Ben Rabizadeh – Fundamentals well positioned with $1B peak sales forecast for orladeyo and $300M i...
February 9, 2022, 4:25 pm
Is biocryst (bcrx) ready to breakout to new highs on recent catalysts?
By Ben Rabizadeh – Fundamentals well positioned with $1B peak sales forecast for orladeyo and $300M i...
February 9, 2022, 4:25 pm
Updated guidance and royalty pharma financing demolish short thesis for biocryst pharmaceuticals
Royalty Pharma and OMERS Capital Markets (OMERS) recently committed $350 million in non-dilutive funding for BioCryst. BioCryst generated $120 million...
February 7, 2022, 11:56 am
Updated guidance and royalty pharma financing demolish short thesis for biocryst pharmaceuticals
Royalty Pharma and OMERS Capital Markets (OMERS) recently committed $350 million in non-dilutive funding for BioCryst. BioCryst generated $120 million...
February 7, 2022, 11:56 am
Updated guidance and royalty pharma financing demolish short thesis for biocryst pharmaceuticals
Royalty Pharma and OMERS Capital Markets (OMERS) recently committed $350 million in non-dilutive funding for BioCryst. BioCryst generated $120 million...
February 7, 2022, 11:56 am
Biocryst to present new orladeyo® (berotralstat) data at 2022 american academy of allergy, asthma & immunology annual meeting
RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will pr...
February 1, 2022, 9:25 am
Biocryst to present new orladeyo® (berotralstat) data at 2022 american academy of allergy, asthma & immunology annual meeting
RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will pr...
February 1, 2022, 9:25 am
Biocryst to present new orladeyo® (berotralstat) data at 2022 american academy of allergy, asthma & immunology annual meeting
RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will pr...
February 1, 2022, 9:25 am